These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 28083711

  • 1. No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib.
    Pfirrmann M, Evtimova D, Saussele S, Castagnetti F, Cervantes F, Janssen J, Hoffmann VS, Gugliotta G, Hehlmann R, Hochhaus A, Hasford J, Baccarani M.
    J Cancer Res Clin Oncol; 2017 May; 143(5):843-850. PubMed ID: 28083711
    [Abstract] [Full Text] [Related]

  • 2. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
    Castagnetti F, Gugliotta G, Breccia M, Iurlo A, Levato L, Albano F, Vigneri P, Abruzzese E, Rossi G, Rupoli S, Cavazzini F, Martino B, Orlandi E, Pregno P, Annunziata M, Usala E, Tiribelli M, Sica S, Bonifacio M, Fava C, Gherlinzoni F, Bocchia M, Soverini S, Bochicchio MT, Cavo M, Giovanni M, Saglio G, Pane F, Baccarani M, Rosti G, GIMEMA CML Working Party.
    Am J Hematol; 2017 Aug; 92(8):797-805. PubMed ID: 28466557
    [Abstract] [Full Text] [Related]

  • 3. Impact of the BCR-ABL1 fusion transcripts on different responses to Imatinib and disease recurrence in Iranian patients with Chronic Myeloid Leukemia.
    Rostami G, Hamid M, Jalaeikhoo H.
    Gene; 2017 Sep 05; 627():202-206. PubMed ID: 28627443
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
    D'Adda M, Farina M, Schieppati F, Borlenghi E, Bottelli C, Cerqui E, Ferrari S, Gramegna D, Pagani C, Passi A, Maifredi A, Tucci A, Capucci MA, Ruggeri G, Rossi G.
    Cancer; 2019 May 15; 125(10):1674-1682. PubMed ID: 30707758
    [Abstract] [Full Text] [Related]

  • 7. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.
    Hanfstein B, Lauseker M, Hehlmann R, Saussele S, Erben P, Dietz C, Fabarius A, Proetel U, Schnittger S, Haferlach C, Krause SW, Schubert J, Einsele H, Hänel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Hofmann WK, Hochhaus A, Müller MC, SAKK and the German CML Study Group.
    Haematologica; 2014 Sep 15; 99(9):1441-7. PubMed ID: 24837466
    [Abstract] [Full Text] [Related]

  • 8. BCR-ABL1 transcript types showed distinct laboratory characteristics in patients with chronic myeloid leukemia.
    Vasconcelos AP, Azevedo IF, Melo FCBC, Neves WB, Azevedo ACAC, Melo RAM.
    Genet Mol Res; 2017 Apr 20; 16(2):. PubMed ID: 28437552
    [Abstract] [Full Text] [Related]

  • 9. Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.
    Lucas CM, Harris RJ, Giannoudis A, Davies A, Knight K, Watmough SJ, Wang L, Clark RE.
    Haematologica; 2009 Oct 20; 94(10):1362-7. PubMed ID: 19713230
    [Abstract] [Full Text] [Related]

  • 10. The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia.
    Ercaliskan A, Eskazan AE.
    Cancer; 2018 Oct 01; 124(19):3806-3818. PubMed ID: 29694669
    [Abstract] [Full Text] [Related]

  • 11. Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia.
    Su YJ, Kuo MC, Chen TY, Wang MC, Yang Y, Ma MC, Lin TL, Lin TH, Chang H, Teng CJ, Hsiao PC, Chen CC, Wang PN, Shih LY.
    Cancer Sci; 2022 Oct 01; 113(10):3518-3527. PubMed ID: 35869805
    [Abstract] [Full Text] [Related]

  • 12. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.
    Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Dyagil I, Glushko N, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Reilly L, Jeynes-Ellis A, Leip E, Bardy-Bouxin N, Hochhaus A, Brümmendorf TH.
    J Clin Oncol; 2018 Jan 20; 36(3):231-237. PubMed ID: 29091516
    [Abstract] [Full Text] [Related]

  • 13. Natural history of Southeast Asian chronic myeloid leukemia patients with different BCR-ABL gene variants.
    Auewarakul CU, Huang S, Yimyam M, Boonmoh S.
    Acta Haematol; 2006 Jan 20; 116(2):114-9. PubMed ID: 16914906
    [Abstract] [Full Text] [Related]

  • 14. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors.
    Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Kanagal Shamanna R, Sasaki K, Jabbour E, Romo CG, Kadia TM, Pemmaraju N, Daver N, Borthakur G, Estrov Z, Ravandi F, O'Brien S, Cortes J.
    Blood; 2016 Mar 10; 127(10):1269-75. PubMed ID: 26729897
    [Abstract] [Full Text] [Related]

  • 15. Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance.
    Zhang J, Wang Y, Wang J, Hu J, Chen S, Jin J, Liu T, Zhou J, Hu Y, Ma D, Huang X, Ji C, Hou M.
    Blood Cancer J; 2018 Jun 15; 8(7):61. PubMed ID: 29915172
    [Abstract] [Full Text] [Related]

  • 16. BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia.
    Pagani IS, Dang P, Kommers IO, Goyne JM, Nicola M, Saunders VA, Braley J, White DL, Yeung DT, Branford S, Hughes TP, Ross DM.
    Haematologica; 2018 Dec 15; 103(12):2026-2032. PubMed ID: 29976745
    [Abstract] [Full Text] [Related]

  • 17. BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR.
    Zagaria A, Anelli L, Coccaro N, Tota G, Casieri P, Cellamare A, Impera L, Brunetti C, Minervini A, Minervini CF, Delia M, Cumbo C, Orsini P, Specchia G, Albano F.
    Virchows Arch; 2015 Sep 15; 467(3):357-63. PubMed ID: 26149409
    [Abstract] [Full Text] [Related]

  • 18. Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients.
    Arun AK, Senthamizhselvi A, Mani S, Vinodhini K, Janet NB, Lakshmi KM, Abraham A, George B, Srivastava A, Srivastava VM, Mathews V, Balasubramanian P.
    Int J Lab Hematol; 2017 Jun 15; 39(3):235-242. PubMed ID: 28035733
    [Abstract] [Full Text] [Related]

  • 19. Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre.
    Qin YZ, Jiang Q, Jiang H, Lai YY, Shi HX, Chen WM, Yu L, Huang XJ.
    Br J Haematol; 2018 Sep 15; 182(5):693-700. PubMed ID: 29974949
    [Abstract] [Full Text] [Related]

  • 20. Molecular response to imatinib in chronic myeloid leukaemia with a variant e13a3 BCR-ABL1 fusion.
    McCarron SL, Langabeer SE, Bolger K, Haslam K, Crampe M, Kelly J, Morrell R.
    Med Oncol; 2015 Feb 15; 32(2):452. PubMed ID: 25579165
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.